A few 2025 trials pointed in the same direction: toward treatments built to modify disease biology and better ways to measure ...

The drug is the second cardiac myosin inhibitor to get regulatory signoff in the United States, following mavacamten in 2022.

Discover why Edgewise Therapeutics, Inc. is rated Buy amid strong trial data, unique HCM treatment, and major 2026 catalysts. Click for this EWTX update.

The Kennedy College of Sciences, Department of Biological Sciences, invites you to attend a Ph.D. Proposal Defense in Applied Biology by Brandon Reder entitled "Morphological and physiological ...

Edgewise announces completion of EDG-7500 CIRRUS-HCM phase 2 parts B & C and favourable interim safety results from the ongoing part D study in hypertrophic cardiomyopathy ...

In the CIRRUS-HCM trial, including interim safety results from Part D, EDG-7500 was generally well tolerated; no clinically meaningful reductions in LVEF or LVEF - - On track to deliver ...

Contractile proteins are proteins that mediate sliding of contractile fibres (contraction) of a cell’s cytoskeleton, and of cardiac and skeletal muscle. Heart and muscle contractile fibres consist of ...

Diets, Food Health Benefits, Diseases, Therapy Share and Cite: Menkovska, M. and Raza, S. (2025) Human Gut Microbiome in ...

Divisions of Chemistry and Biological Sciences, Graduate School of Science, Hokkaido University, Sapporo 060-0810, Japan, and Celestar Lexico-Sciences, Inc., Chiba 261-8501, Japan Article Views are ...